$AVXL: Anavex signs a material transfer agreement
Post# of 22755
Posted On: 09/28/2016 9:33:13 AM
$AVXL: Anavex signs a material transfer agreement with Biogen (BIIB) under which Biogen will test ANAVEX 2-73 in an oligodendrocyte precursor cell differentiation assay
"Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
"Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
(2)
(0)Scroll down for more posts ▼